Klaus H. Kaestner, Ph.D.

faculty photo
Thomas and Evelyn Suor Butterworth Professor in Genetics
Associate Director, Diabetes Research Center, University of Pennsylvania Perelman School of Medicine
Department: Genetics

Contact information
12-126 Translational Research Center
3400 Civic Center Blvd
Philadelphia, PA 19104-6145
Office: 215-898-8759
Fax: 215-573-5892
Education:
B.S. (Biology and Chemistry)
Universität Bremen, 1984.
M.S.
University of Maryland, College Park, 1986.
Ph.D.
Johns Hopkins University Medical School, 1990.
Permanent link
 
> Perelman School of Medicine   > Faculty   > Details

Description of Research Expertise

Research Interests
Dr. Kaestner’s lab is employing modern genetic, genomic and epigenomic approaches (ChIP-Seq, RNA-Seq, gene targeting, tissue-specific and inducible gene ablation, CyTOF) to understand the molecular mechanisms of organogenesis and physiology of the liver, pancreas and gastrointestinal tract. Disease areas targeted by our research include diabetes and cancer.

Description of Research
Epigenomic rejuvenation of human pancreatic beta-cells.

The prevalence of Diabetes Mellitus has reached epidemic proportions world-wide, and is predicted to increase rapidly in the years to come, putting a tremendous strain on health care budgets in both developed and developing countries. There are two major forms of diabetes and both are associated with decreased beta-cell mass. No treatments have been devised that increase beta-cell mass in vivo in humans, and transplantation of beta-cells is extremely limited due to lack of appropriate donors. For these reasons, increasing functional beta-cell mass in vitro, or in vivo prior to or after transplantation, has become a “Holy Grail” of diabetes research. Our previous studies clearly show that adult human beta-cells can be induced to replicate, and – importantly - that cells can maintain normal glucose responsiveness after cell division. However, the replication rate achieved was still low, likely due in part to the known age-related decline in the ability of the beta-cell to replicate. We propose to build on our previous findings and to develop more efficacious methods to increase functional beta-cell mass by inducing replication of adult beta-cells, and by restoring juvenile functional properties to aged beta-cells. We will focus on mechanisms derived from studies of non-neoplastic human disease as well as age-related phenotypic changes in human beta-cells. In Aim 1, we will target the genes altered in patients with marked beta-cell hyperplasia, such as those suffering from Beckwith-Wiedemann Syndrome or Multiple Endocrine Neoplasia. Expression of these genes will be altered in human beta-cells via shRNA-mediated gene suppression and locus-specific epigenetic targeting. Success will be assessed in transplanted human islets by determination of beta-cell replication rate and retention of function. In Aim 2, we will determine the mechanisms of age-related decline in beta-cell function and replicative capacity, by mapping the changes in the beta-cell epigenome that occur with age. Selected genes will then be targeted as in Aim 1 to improve human beta-cell function, as assessed by glucose responsiveness. To accomplish these aims, we will use cutting-edge and emerging technologies that are already established or are being developed in our laboratories. The research team combines clinical experience with expertise in molecular biology and extensive experience in genomic modification aimed at enhancing beta-cell replication. By basing interventions on changes found in human disease and normal aging, this approach will increase the chances that discoveries made can be translated more rapidly into clinically relevant protocols.

Regulatory cascades in differentiation and proliferation of the gastrointestinal epithelium.

The mammalian gut epithelium is a highly organized and dynamic system which requires continuous controlled proliferation and differentiation throughout life. Proliferation, cell migration and cell adhesion all must be tightly controlled in order to prevent either inflammatory diseases or epithelial cancers. Stem cell niches provide essential signals and growth factors to sustain proliferation and self-renewal of stem cells in regenerative organs such as the intestine. Here, we identify subepithelial telocytes as an obligatory source of Wnt proteins, without which intestinal stem cells cannot be maintained. Telocytes are large but rare mesenchymal cells that are marked by Foxl1 and PDGFRα expression and form a subepithelial plexus that extends from the stomach to the colon. While supporting the entire epithelium, Foxl1+ telocytes compartmentalize the production of Wnt ligands and inhibitors to enable localized pathway activation. Conditional gene ablation of Porcupine (Porcn), which is required for functional maturation of all Wnt proteins, in Foxl1+ telocytes causes cessation of Wnt signaling to intestinal crypts, loss of stem cell proliferation, and death of mutant mice within four days of tamoxifen treatment. Thus, Foxl1+ telocytes are the critical source of niche signals to intestinal stem cells..

Innovative Genetic Approaches for Hepatic Repopulation

A better understanding of the liver’s response to toxic injury, which includes hepatocyte proliferation, activation and differentiation of facultative hepatic stem cells (“oval cells”), and – unfortunately – an increased risk for hepatocellular carcinoma, is a prerequisite for the development of novel clinical treatments for chronic liver disease and improved cancer prevention. Likewise, cell replacement therapy, either through direct hepatocyte transplantation or in bio-artificial liver devices, needs to be improved in order to become a reliable alternative to liver transplantation. To date, investigations of hepatocyte proliferation have frequently focused on the partial hepatectomy paradigm, a “non¬injury” model that is not reflective of liver injury in humans and which has therefore failed to identify specific targets for either improved regeneration following toxic injury or for limiting proliferation in HCC in humans. We will determine which genes and gene combinations promote or repress hepatocyte repopulation following toxic liver injury using an innovative genetic approach. I Together, these approaches will provide an improved understanding of the liver’s response to toxic injury, and facilitate the discovery of new cell replacement therapies to treat chronic liver disease and liver failure.


Rotation Projects for 2022/23

1. Analysis and integration of complex epigenomic data sets

2. Molecular, histological and metabolic analysis of mouse models of diabetes, intestinal stem cell niche, and gastrointestinal cancer.

3. ChIP-Seq analysis. Chromatin immunoprecipitation using various transcription factor or modified histone antibodies. Library construction, ultra-high throughput sequencing and computational analysis of target sequences.

Lab Personnel:

Dr. Suzanne Shapira, Program Coordinator, Human Pancreas Analysis Program

Melissa Rowe, Graduate Student
Eric Waite, Graduate Student
Varun Bahl, Graduate Student
Hannah Kolev, Graduate Student
Michelle Lee, Graduate Student

Dr. Omar Guessoum, Posdoc
Dr. Guoli Zhu, Postdoc
Dr. Avital Swisa, Postdoc

Dr. Helene Descamp, Staff Scientist
Dr. Elisabetta Manduchi, Staff Scientist

Deeksha Lahori, Research Specialist
Daniel Traum, Research Specialist
Hilana El-Mekoussi, Research Specialist
Kate Huguney-Axley, Research Specialist

Selected Publications

Bahl V, Rifkind R, Waite E, Hamdan Z, May CL, Manduchi E, Voight BF, Lee MYY, Tigue M, Manuto N, Glaser B, Avrahami D, Kaestner KH.: G6PC2 controls glucagon secretion by defining the set point for glucose in pancreatic α cells. Sci Transl Med 17(779): eadi6148, January 2025.

Matrenec R, Oropeza CE, Dekoven E, Matrenec C, Maienschein-Cline M, Chau CS, Green SJ, Kaestner KH, McLachlan A.: Foxa deficiency restricts hepatitis B virus biosynthesis through epigenic silencing. J Virol 98: e0137124, Nov 2024.

Waite EL, Tigue M, Yu M, Lahori D, Kelly K, May CL, Naji A, Roman J, Doliba N, Avrahami D, Nguyen-Ngoc KV, Sander M, Glaser B, Kaestner KH.: The IsletTester mouse: an immunodeficient model with stable hyperglycemia for the study of human islets. Diabetes online ahead of print, November 2024.

Ma X, Dawany N, Kondo A, Maurer K, Karakasheva T, Shraim R, Williams PA, Parham LR, Simon LA, Danan CH, Conrad MA, Piccoli DA, Devoto M, Sullivan KE, Kaestner KH, Kelsen JR, Hamilton KE.: TNFSF13 insufficiency disrupts human colonic epithelial cell-mediated B cell differentiation. bioRxiv Sep 2024.

Manduchi, E., Descamp, H.C., Schug, J., Da, T., Lahori, D., El-Mekkoussi, H., Betts, M.R., and Kaestner, K.H.: No evidence for persistent enteroviral B infection of pancreatic islets in type 1 diabetic and pre-diabetic patients from RNA-Seq data. Diabetes Online ahead of print, September 2024.

Golden GJ, Wu VH, Hamilton JT, Amses KR, Shapiro MR, Japp AS, Liu C, Pampena MB, Kuri-Cervantes L, Knox JJ, Gardner JS; HPAP Consortium; Atkinson MA, Brusko TM, Prak ETL, Kaestner KH, Naji A, Betts MR.: Immune perturbations in human pancreas lymphatic tissues prior to and after type 1 diabetes onset. bioRxiv Sep 2024.

Trang KB, Sharma P, Cook L, Mount Z, Thomas RM, Kulkarni NN, Pahl MC, Pippin JA, Su C, Kaestner KH, O'Brien JM, Wagley Y, Hankenson KD, Jermusyk A, Hoskins JW, Amundadottir LT, Xu M, Brown KM, Anderson SA, Yang W, Titchenell PM, Seale P, Zemel BS, Chesi A, Romberg N, Levings MK, Grant SFA, Wells AD.: 3D chromatin-based variant-to-gene maps across 57 human cell types reveal the cellular and genetic architecture of autoimmune disease susceptibility. medRxiv Aug 2024.

Abedini A, Levinsohn J, Klötzer KA, Dumoulin B, Ma Z, Frederick J, Dhillon P, Balzer MS, Shrestha R, Liu H, Vitale S, Bergeson AM, Devalaraja-Narashimha K, Grandi P, Bhattacharyya T, Hu E, Pullen SS, Boustany-Kari CM, Guarnieri P, Karihaloo A, Traum D, Yan H, Coleman K, Palmer M, Sarov-Blat L, Morton L, Hunter CA, Kaestner KH, Li M, Susztak K.: Single-cell multi-omic and spatial profiling of human kidneys implicates the fibrotic microenvironment in kidney disease progression. Nat Genet 56(8): 1712-1724, August 2024.

Trang KB, Chesi A, Toikumo S, Pippin JA, Pahl MC, O'Brien JM, Amundadottir LT, Brown KM, Yang W, Welles J, Santoleri D, Titchenell PM, Seale P, Zemel BS, Wagley Y, Hankenson KD, Kaestner KH, Anderson SA, Kayser MS, Wells AD, Kranzler HR, Kember RL, Grant SFA.: Shared and unique 3D genomic features of substance use disorders across multiple cell types. medRxiv Jul 2024.

Liu L, Ei K, Dattaroy D, Barella LF, Cui Y, Gray SM, Guedikian C, Chen M, Weinstein LS, Knuth E, Jin E, Merrins MJ, Roman J, Kaestner KH, Doliba N, Campbell JE, Wess J.: Intra-islet α-cell Gs signaling promotes glucagon release. Nat Commun 15: 5129, Jun 2024.

back to top
Last updated: 01/05/2025
The Trustees of the University of Pennsylvania